Gyre Therapeutics (GYRE) Total Current Liabilities (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Total Current Liabilities data on file, last reported at $19.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $19.8 million, up 4.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.8 million (up 4.2% YoY), and the FY2025 annual result was $18.3 million, down 6.3% from the prior year.
• Total Current Liabilities grew to $19.8 million in Q1 2026 per GYRE's latest filing, from $18.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $20.0 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
• A 5-year average of $13.1 million and a median of $15.6 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities sank 90.47% in 2022, then surged 725.35% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $12.2 million in 2022, then jumped by 63.76% to $20.0 million in 2023, then declined by 2.65% to $19.5 million in 2024, then dropped by 6.3% to $18.3 million in 2025, then advanced by 8.21% to $19.8 million in 2026.
• Business Quant data shows GYRE's Total Current Liabilities at $19.8 million in Q1 2026, $18.3 million in Q4 2025, and $15.9 million in Q3 2025.